Core Viewpoint - The company, Guichuang Tongqiao, reported significant revenue growth driven by its neurovascular and peripheral vascular intervention products, with a focus on enhancing operational efficiency and organic revenue growth [1][2]. Financial Performance - For the six months ending June 30, 2025, the company achieved revenue of RMB 482.0 million, a 31.7% increase from RMB 366.0 million in the first half of 2024 [1]. - The net profit under International Financial Reporting Standards (IFRS) was RMB 121.2 million, up 76.0% from the previous year's RMB 68.8 million [1]. - The adjusted non-IFRS net profit was RMB 131.4 million, reflecting a 68.1% increase from RMB 78.2 million in the first half of 2024 [1]. Research and Development - The company's R&D expenditure for the first half of 2025 was RMB 121.6 million, a 19.7% increase from RMB 101.5 million in the same period of 2024, driven by the introduction of more products and innovative solutions [1][2]. International Business Expansion - The international business generated revenue of RMB 15.7 million, a 36.9% increase compared to the same period in 2024, primarily from Europe and Asia [2]. - The company has established a presence in 27 countries/regions with 22 products, focusing on deepening its market penetration in Europe and expanding into emerging markets like Brazil, India, and South Africa [2]. Clinical Trials and Product Recognition - The company is conducting post-market clinical follow-up trials in Europe to establish product quality recognition, which is crucial for demonstrating clinical value and obtaining EU MDR certification [3]. - The products have gained recognition from leading hospital groups globally, including Asklepios and SANA, with over 31 products registered in more than 23 countries/regions [3].

Group 1 - The company reported a revenue of 482 million RMB for the six months ending June 30, 2025, representing a year-on-year increase of 31.69% [1] - Gross profit reached 343 million RMB, with a year-on-year increase of 31.5% [1] - Shareholders' profit attributable to the company was 121 million RMB, marking a significant year-on-year increase of 76% [1] - Basic earnings per share were 0.38 RMB [1] Group 2 - 63.3% of the company's revenue came from neurovascular intervention products, while 36.7% was from peripheral vascular intervention products [1] - The significant revenue growth was primarily driven by the rapid sales increase in neurovascular and peripheral vascular intervention devices [1] - Neurovascular intervention product sales increased by 25.0% in the first half of 2025 compared to the same period in 2024, attributed to the strong performance of key mature products and the introduction of newer products [1] Group 3 - The company has launched 50 products in the Chinese market, solidifying its leading position in the neurovascular and peripheral vascular intervention medical device industry [2] - Since the launch of a major product at the end of 2020, the company has established a broad distribution network covering over 3,000 hospitals and clinical use of over 1 million medical devices [2] - The company's professional sales and marketing team has built strong trust with doctors, enhancing clinical recognition and effectively translating strong R&D capabilities into commercial success [2]

Financial Performance - The company reported a revenue of 482 million RMB for the six months ending June 30, 2025, representing a year-on-year increase of 31.69% [1] - Gross profit reached 343 million RMB, up 31.5% year-on-year [1] - Shareholder profit attributable to the company was 121 million RMB, a significant increase of 76% compared to the previous year [1] - Basic earnings per share were 0.38 RMB [1] Product Segmentation - 63.3% of the company's revenue came from neurovascular intervention products, while 36.7% was from peripheral vascular intervention products [1] - The significant revenue growth was primarily driven by the rapid sales increase in both neurovascular and peripheral vascular intervention devices [1] Sales Growth Drivers - Neurovascular intervention product sales increased by 25.0% in the first half of 2025 compared to the first half of 2024, attributed to several factors: - Substantial revenue growth from key mature products such as the Silver Snake intracranial intermediate catheter series, Phoenix intracranial aneurysm embolization coils, and neurovascular guidewires [1] - Launch of newer products like the Qilin blood flow guiding device following large-scale centralized procurement in hospitals [1] - Ongoing efforts to enhance product penetration across various levels of hospitals [1] Market Position and Distribution - The company has launched 50 products in the Chinese market, solidifying its leading position in the neurovascular and peripheral vascular intervention medical device industry [2] - Since the launch of a major product at the end of 2020, the company has established a broad distribution network covering over 3,000 hospitals, with clinical use of medical devices exceeding 1 million [2] - The company has built strong trust with doctors through its professional sales and marketing teams, effectively translating its robust R&D capabilities into commercial success [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Zylox-Tonbridge Medical Technology Co., Ltd. 歸創通橋醫療科技股份有限公司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：2190） 截至2025年6月30日止六個月的中期業績公告 歸創通橋醫療科技股份有限公司（「本公司」）董事（「董事」）會（「董事會」）欣然 宣佈本公司及其附屬公司（統稱為「本集團」）截至2025年6月30日止六個月的未 經審核簡明綜合中期業績，連同截至2024年6月30日止六個月的比較數字。 | 財務摘要 | | | | | --- | --- | --- | --- | | 截至6月30日止六個月 | | | | | 2025年 | | 2024年 | 同比變動 | | 人民幣千元 | 人民幣千元 | | | | （未經審核）（未經審核） | | | | | 收入 | 481,969 | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 歸創通橋醫療科技股份有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02190 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 322,400,744 | RMB | | 1 RMB | | 322,400,744 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 322,400,744 | RMB | | 1 RMB | | 322,400,744 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 ( ...

Group 1: Market Overview - The Hang Seng Index rose by 0.40%, gaining 102 points to close at 25,490 points, while the Hang Seng Tech Index fell by 0.59% [1] - Hong Kong's stock market saw a morning trading volume of HKD 149.7 billion [1] Group 2: Brokerage Performance - The establishment of the China Capital Market Society has led to positive performance reports from listed brokerages, with notable gains in shares such as Guotai Junan (up 3%), Everbright Securities (up 0.54%), and CITIC Securities (up 1%) [1] Group 3: Gaming Sector - UBS reported that Macau's July gaming revenue exceeded market expectations, while Thailand recently withdrew its casino legalization bill, leading to a rise in gaming stocks. Notable increases include Suncity Holdings (up 7.79%), Melco International Development (up 3.89%), and Sands China (up 1.62%) [1] Group 4: Financial Technology and Digital Currency - Yunfeng Financial rose by 5.68% as the company plans to enter the Web 3.0 space and expand investments in stablecoins and other digital currencies [1] - OSL Group announced the completion of a USD 300 million equity financing, which will be used for license application preparations and other core areas, resulting in a 2.68% increase in its stock [1] Group 5: Innovative Products and Earnings - Guichuang Tongqiao saw a nearly 6% increase, with expected net profit growth of nearly 67% year-on-year for the first half, and several innovative products anticipated to receive approval [1] - China Tobacco Hong Kong surged over 13%, indicating that its exclusive cigarette export business is unaffected by related regulatory draft [1] Group 6: Optical Technology - Conant Optical experienced a rise of over 6%, driven by the upward trend in smart glasses and the potential growth of its XR business [2] Group 7: Gold and Coal Sectors - Laopu Gold's stock fell nearly 4% after a profit warning, despite a projected net profit increase of up to 288% year-on-year for the first half [3] - The main contracts for coking coal saw significant declines, with companies like Mongolian Coking Coal and Yancoal Australia dropping by 5% and 3.39% respectively, indicating a need to monitor policy developments [3]

Group 1: Market Overview - The Hang Seng Index fell by 1.11%, down 284 points, closing at 25,383 points, while the Hang Seng Tech Index dropped by 1.69% [1] - The early trading volume in Hong Kong stocks reached 151 billion HKD [1] Group 2: Medical Sector - Medical device stocks rose in early trading, with the national drug procurement policy indicating a move away from internal competition, leading institutions to view this as a turning point for the industry [1] - Aikang Medical (01789) increased by 7.93%, and Weigao Group (01066) rose by 4.37% [1] - Yongsheng Medical (01612) saw a surge of over 27% following a profit warning, with sales orders increasing and expected mid-term net profit growth exceeding 50% year-on-year [2] - CRO concept stocks continued to rise, with Citigroup noting that the CXO sector is gaining market attention ahead of earnings season [2] - Kanglong Chemical (300759) (03759) rose by 8.4%, while Zhaoyan New Drug (603127) (06127) increased by 5.7%, and WuXi Biologics (02269) rose by 4.5% [2] Group 3: Consumer Sector - Nongfu Spring (09633) increased by over 3.56%, reaching a three-and-a-half-year high, with institutions expecting the company's first-half revenue growth to exceed market expectations [3] Group 4: Other Notable Stocks - Jihong Co., Ltd. (002803) (02603) rose by 16%, with two main business segments performing well, and expected first-half net profit growth of up to 65% [4] - China Merchants Port (01199) increased by over 4%, following reports that China Merchants Group plans to acquire assets from Cheung Kong Ports [5] - Guichuang Tongqiao (02190) rose by 2.6%, with expected mid-term net profit growth of 66.9%, as the company embraces procurement and actively expands overseas [6] Group 5: Lithium and Duty-Free Sector - News of supply disruptions in the lithium market led to Tianqi Lithium (002466) (09696) rising by 3.6% [7] - China Duty Free Group (601888) (01880) fell by over 6%, with pending details on Hainan's duty-free policies, and institutions noting that the closure operations have a dual impact on offshore duty-free business [7] Group 6: Technology Sector - Qianxun Technology (01640) fell by over 3%, having retreated 23% from its previous high, with recent comments from Yu Weiwen emphasizing the need to avoid excessive speculation on stablecoins [8]

Summary of Key Points Core Viewpoint - On July 18, 22 Hong Kong-listed companies conducted share buybacks, totaling 13.19 million shares and an aggregate amount of HKD 36.71 million [1][2]. Group 1: Buyback Details - VITASOY INT'L repurchased 1.044 million shares for HKD 9.67 million, with a highest price of HKD 9.260 and a lowest price of HKD 9.250, bringing its total buyback amount for the year to HKD 137.23 million [1][2]. - China International Marine Containers (CIMC) bought back 1.263 million shares for HKD 8.69 million, with a highest price of HKD 7.020 and a lowest price of HKD 6.700, totaling HKD 56.01 million in buybacks for the year [1][2]. - China Eastern Airlines repurchased 1.75 million shares for HKD 5.04 million, with a highest price of HKD 2.940 and a lowest price of HKD 2.850, accumulating HKD 575.79 million in buybacks this year [1][2]. Group 2: Buyback Rankings - The highest buyback amount on July 18 was from VITASOY INT'L at HKD 9.67 million, followed by CIMC at HKD 8.69 million, and China Eastern Airlines also featured prominently [1][2]. - In terms of share quantity, the largest buyback was by Ying Group with 3 million shares, followed by Sincere International and China Eastern Airlines with 2 million and 1.75 million shares respectively [1][2].

Summary of Key Points Core Viewpoint - Multiple companies conducted share buybacks on July 18, 2025, with VITASOY INT'L leading in terms of buyback amount and quantity [1][2]. Company Buyback Details - **VITASOY INT'L (00345)**: - Buyback quantity: 1.044 million shares - Buyback amount: 9.6671 million [2] - Year-to-date buyback quantity: 14.574 million shares, representing 1.358% of total shares [2] - **中集集团 (02039)**: - Buyback quantity: 1.263 million shares - Buyback amount: 8.6893 million [2] - Year-to-date buyback quantity: 8.6108 million shares, representing 0.280% of total shares [2] - **百胜中国 (09987)**: - Buyback quantity: 16,500 shares - Buyback amount: 6.2518 million [2] - Year-to-date buyback quantity: 2.8399 million shares, representing 0.760% of total shares [2] - **中国东方航空股份 (00670)**: - Buyback quantity: 1.750 million shares - Buyback amount: 5.0398 million [2] - Year-to-date buyback quantity: 96.208 million shares, representing 1.859% of total shares [2] - **贝壳-W (02423)**: - Buyback quantity: 634,900 shares - Buyback amount: 4 million [2] - Year-to-date buyback quantity: 1.0836 million shares, representing 0.300% of total shares [2] Additional Companies Involved - **蒙牛乳业 (02319)**: - Buyback quantity: 200,000 shares - Buyback amount: 3.393 million [2] - Year-to-date buyback quantity: 4.75 million shares, representing 0.121% of total shares [2] - **信利国际 (00732)**: - Buyback quantity: 2 million shares - Buyback amount: 2.4 million [2] - Year-to-date buyback quantity: 44.522 million shares, representing 1.408% of total shares [2] - **名创优品 (09896)**: - Buyback quantity: 57,000 shares - Buyback amount: 1.9943 million [2] - Year-to-date buyback quantity: 2.7211 million shares, representing 0.219% of total shares [2] Summary of Buyback Trends - The buyback activities indicate a trend among companies to return capital to shareholders, with varying levels of commitment reflected in the percentage of total shares repurchased [1][2].

Summary of Key Points Core Viewpoint - Multiple companies conducted share buybacks on July 17, 2025, with notable amounts and quantities involved, indicating a trend of companies returning capital to shareholders [1]. Group 1: Buyback Details - The largest buyback was executed by Green Bamboo Bio-B (02480), with a total of 316,600 shares repurchased for an amount of 6.8407 million [2]. - China Eastern Airlines (00670) repurchased 2.2 million shares for 6.4249 million, representing 1.825% of its total share capital [2]. - CIMC (02039) bought back 656,200 shares for 4.5029 million, accounting for 0.240% of its total share capital [2]. Group 2: Other Notable Buybacks - Mengniu Dairy (02319) repurchased 200,000 shares for 3.3682 million, which is 0.116% of its total share capital [2]. - China Xuyang Group (01907) bought back 1.04 million shares for 2.6279 million, representing 0.971% of its total share capital [2]. - Miniso (09896) repurchased 57,400 shares for 1.9974 million, which is 0.210% of its total share capital [2]. Group 3: Additional Companies - Other companies such as IGG (00799) and HYPEBEAST (00150) also participated in buybacks, with IGG repurchasing 246,000 shares for 1.0630 million and HYPEBEAST repurchasing 3,001,600 shares for 469,300 [2]. - The buyback activities reflect a broader strategy among these companies to enhance shareholder value and confidence in their financial health [1].